Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1977 1
1978 1
1979 3
1980 4
1981 6
1982 7
1983 8
1984 7
1985 10
1986 9
1987 15
1988 11
1989 27
1990 25
1991 23
1992 22
1993 28
1994 28
1995 31
1996 52
1997 54
1998 59
1999 67
2000 67
2001 79
2002 70
2003 83
2004 137
2005 126
2006 125
2007 160
2008 189
2009 205
2010 254
2011 292
2012 327
2013 379
2014 437
2015 463
2016 369
2017 284
2018 411
2019 503
2020 571
2021 670
2022 596
2023 568
2024 146

Text availability

Article attribute

Article type

Publication date

Search Results

7,168 results

Results by year

Filters applied: . Clear all
Page 1
CAR-T design: Elements and their synergistic function.
Jayaraman J, Mellody MP, Hou AJ, Desai RP, Fung AW, Pham AHT, Chen YY, Zhao W. Jayaraman J, et al. Among authors: pham aht. EBioMedicine. 2020 Aug;58:102931. doi: 10.1016/j.ebiom.2020.102931. Epub 2020 Jul 30. EBioMedicine. 2020. PMID: 32739874 Free PMC article. Review.
Chimeric antigen receptor (CAR) T cells use re-engineered cell surface receptors to specifically bind to and lyse oncogenic cells. Two clinically approved CAR-T-cell therapies have significant clinical efficacy in treating CD19-positive B cell cancers. ...
Chimeric antigen receptor (CAR) T cells use re-engineered cell surface receptors to specifically bind to and lyse oncogenic cells. Tw …
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis.
Piper M, Hoen M, Darragh LB, Knitz MW, Nguyen D, Gadwa J, Durini G, Karakoc I, Grier A, Neupert B, Van Court B, Abdelazeem KNM, Yu J, Olimpo NA, Corbo S, Ross RB, Pham TT, Joshi M, Kedl RM, Saviola AJ, Amann M, Umaña P, Codarri Deak L, Klein C, D'Alessandro A, Karam SD. Piper M, et al. Among authors: pham tt. Cancer Cell. 2023 May 8;41(5):950-969.e6. doi: 10.1016/j.ccell.2023.04.001. Epub 2023 Apr 27. Cancer Cell. 2023. PMID: 37116489 Free PMC article.
The bispecific PD1-IL2v is a PD-1-targeted IL-2 variant (IL-2v) immunocytokine with engineered IL-2 cis targeted to PD-1 and abolished IL-2Ralpha binding, which enhances tumor-antigen-specific T cell activation while reducing regulatory T cell (Treg) suppression. .. …
The bispecific PD1-IL2v is a PD-1-targeted IL-2 variant (IL-2v) immunocytokine with engineered IL-2 cis targeted to PD-1 and abolished IL-2R …
Efficient tumor killing and minimal cytokine release with novel T-cell agonist bispecific antibodies.
Trinklein ND, Pham D, Schellenberger U, Buelow B, Boudreau A, Choudhry P, Clarke SC, Dang K, Harris KE, Iyer S, Jorgensen B, Pratap PP, Rangaswamy US, Ugamraj HS, Vafa O, Wiita AP, van Schooten W, Buelow R, Force Aldred S. Trinklein ND, et al. Among authors: pham d. MAbs. 2019 May/Jun;11(4):639-652. doi: 10.1080/19420862.2019.1574521. Epub 2019 Feb 20. MAbs. 2019. PMID: 30698484 Free PMC article.
T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing activity in humans, but cytokine release-related toxicities have affected their clinical utility. ...In T-BsAb format, 12 different anti-CD3 arms induce equivalent levels of tum …
T-cell-recruiting bispecific antibodies (T-BsAbs) have shown potent tumor killing activity in humans, but cytokine release-rel …
T cells from patients with Parkinson's disease recognize alpha-synuclein peptides.
Sulzer D, Alcalay RN, Garretti F, Cote L, Kanter E, Agin-Liebes J, Liong C, McMurtrey C, Hildebrand WH, Mao X, Dawson VL, Dawson TM, Oseroff C, Pham J, Sidney J, Dillon MB, Carpenter C, Weiskopf D, Phillips E, Mallal S, Peters B, Frazier A, Lindestam Arlehamn CS, Sette A. Sulzer D, et al. Among authors: pham j. Nature. 2017 Jun 29;546(7660):656-661. doi: 10.1038/nature22815. Epub 2017 Jun 21. Nature. 2017. PMID: 28636593 Free PMC article.
Here we show that a defined set of peptides that are derived from alpha-synuclein, a protein aggregated in Parkinson's disease, act as antigenic epitopes displayed by these alleles and drive helper and cytotoxic T cell responses in patients with Parkinson's disease. These …
Here we show that a defined set of peptides that are derived from alpha-synuclein, a protein aggregated in Parkinson's disease, act as antig …
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release.
Dang K, Castello G, Clarke SC, Li Y, Balasubramani A, Boudreau A, Davison L, Harris KE, Pham D, Sankaran P, Ugamraj HS, Deng R, Kwek S, Starzinski A, Iyer S, van Schooten W, Schellenberger U, Sun W, Trinklein ND, Buelow R, Buelow B, Fong L, Dalvi P. Dang K, et al. Among authors: pham d. J Immunother Cancer. 2021 Jun;9(6):e002488. doi: 10.1136/jitc-2021-002488. J Immunother Cancer. 2021. PMID: 34088740 Free PMC article.
Therefore, the development of novel and effective therapies for mCRPC represents an urgent medical need. T cell engagers (TCEs) have emerged as a promising approach for the treatment of mCRPC due to their targeted mechanism of action. ...RESULTS: In vitro, TNB-585 induced …
Therefore, the development of novel and effective therapies for mCRPC represents an urgent medical need. T cell engagers (TCEs) have …
Programmable multispecific DNA-origami-based T-cell engagers.
Wagenbauer KF, Pham N, Gottschlich A, Kick B, Kozina V, Frank C, Trninic D, Stömmer P, Grünmeier R, Carlini E, Tsiverioti CA, Kobold S, Funke JJ, Dietz H. Wagenbauer KF, et al. Among authors: pham n. Nat Nanotechnol. 2023 Nov;18(11):1319-1326. doi: 10.1038/s41565-023-01471-7. Epub 2023 Aug 17. Nat Nanotechnol. 2023. PMID: 37591933 Free PMC article.
We screened 105 distinct quadruplet antibody variants in vitro for the ability to activate T cells in the presence of target cells. T-cell engagers were identified, which in vitro showed the specific and efficient T-cell-mediated lysis of five distinct target …
We screened 105 distinct quadruplet antibody variants in vitro for the ability to activate T cells in the presence of target cells. …
Quantitative control of Ets1 dosage by a multi-enhancer hub promotes Th1 cell differentiation and protects from allergic inflammation.
Chandra A, Yoon S, Michieletto MF, Goldman N, Ferrari EK, Abedi M, Johnson I, Fasolino M, Pham K, Joannas L, Kee BL, Henao-Mejia J, Vahedi G. Chandra A, et al. Among authors: pham k. Immunity. 2023 Jul 11;56(7):1451-1467.e12. doi: 10.1016/j.immuni.2023.05.004. Epub 2023 May 31. Immunity. 2023. PMID: 37263273 Free PMC article.
Here, we studied the functional relevance of these three-dimensional structures in T cell biology. Mathematical modeling identified a highly connected multi-enhancer hub at the Ets1 locus, comprising a noncoding regulatory element that was a hotspot for sequence variation …
Here, we studied the functional relevance of these three-dimensional structures in T cell biology. Mathematical modeling identified a …
T Cell Response to SARS-CoV-2 Coinfection and Comorbidities.
Wang L, Peng HY, Pham A, Villazana E, Ballard DJ, Das JK, Kumar A, Xiong X, Song J. Wang L, et al. Among authors: pham a. Pathogens. 2023 Feb 15;12(2):321. doi: 10.3390/pathogens12020321. Pathogens. 2023. PMID: 36839596 Free PMC article. Review.
However, human health and T cell responses are also impacted by many other pathogens and chronic diseases. ...We have summarized whether changes in T cell response influence the clinical outcome during comorbidities....
However, human health and T cell responses are also impacted by many other pathogens and chronic diseases. ...We have summarized whet …
Modulating T-cell-based cancer immunotherapy via particulate systems.
Truong DH, Tran TTP, Nguyen HT, Phung CD, Pham TT, Yong CS, Kim JO, Tran TH. Truong DH, et al. Among authors: pham tt. J Drug Target. 2019 Feb;27(2):145-163. doi: 10.1080/1061186X.2018.1474360. Epub 2018 Jun 3. J Drug Target. 2019. PMID: 29741964 Review.
Immunotherapy holds tremendous promise for improving cancer treatment in which an appropriate stimulator may naturally trigger the immune system to control cancer. Up-to-date, adoptive T-cell therapy has received two new FDA approvals that provide great hope for some cance …
Immunotherapy holds tremendous promise for improving cancer treatment in which an appropriate stimulator may naturally trigger the immune sy …
Kruppel-like factor 2+ CD4 T cells avert microbiota-induced intestinal inflammation.
Shao TY, Jiang TT, Stevens J, Russi AE, Troutman TD, Bernieh A, Pham G, Erickson JJ, Eshleman EM, Alenghat T, Jameson SC, Hogquist KA, Weaver CT, Haslam DB, Deshmukh H, Way SS. Shao TY, et al. Among authors: pham g. Cell Rep. 2023 Nov 28;42(11):113323. doi: 10.1016/j.celrep.2023.113323. Epub 2023 Oct 26. Cell Rep. 2023. PMID: 37889750 Free PMC article.
CD4 cells with commensal specificity in secondary lymphoid organs and intestinal tissues are enriched for KLF2 expression, and distinct from FOXP3+ regulatory T cells or other differentiation lineages. Mice with conditional KLF2 deficiency in T cells develop spontan …
CD4 cells with commensal specificity in secondary lymphoid organs and intestinal tissues are enriched for KLF2 expression, and distinct from …
7,168 results